Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer

in Endocrine Oncology
Authors:
Donatella TreppiediD Treppiedi, Department of Clinical Sciences and Community Health, , University of Milan, Milano, Italy

Search for other papers by Donatella Treppiedi in
Current site
Google Scholar
PubMed
Close
,
Rosa CatalanoR Catalano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy

Search for other papers by Rosa Catalano in
Current site
Google Scholar
PubMed
Close
,
Federica MangiliF Mangili, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy

Search for other papers by Federica Mangili in
Current site
Google Scholar
PubMed
Close
,
Giovanna MantovaniG Mantovani, Department of Clinical Sciences and Community Health, University of Milan, Milano, 20122, Italy

Search for other papers by Giovanna Mantovani in
Current site
Google Scholar
PubMed
Close
, and
Erika PeverelliE Peverelli, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy

Search for other papers by Erika Peverelli in
Current site
Google Scholar
PubMed
Close

Correspondence: Giovanna Mantovani, Email: giovanna.mantovani@unimi.it
Open access

Cell cytoskeleton proteins are involved in tumor pathogenesis, progression and pharmacological resistance. Filamin A (FLNA) is a large actin-binding protein with both structural and scaffold functions implicated in a variety of cellular processes, including migration, cell adhesion, differentiation, proliferation and transcription. The role of FLNA in cancers has been studied in multiple types of tumors. FLNA plays a dual role in tumors, depending on its subcellular localization, post-translational modification (as phosphorylation at Ser2125) and interaction with binding partners. This review summarizes the experimental evidence showing the critical involvement of FLNA in the complex biology of endocrine tumors. Particularly, it will be discussed the role of FLNA in regulating expression and signaling of the main pharmacological targets in pituitary neuroendocrine tumors (PitNETs), pancreatic neuroendocrine tumors (Pan-NETs), pulmonary neuroendocrine tumors (P-NETs) and adrenocortical carcinomas (ACC), with implications on responsiveness to currently used drugs in the treatment of these tumors.

 

  • Collapse
  • Expand

Society for Endocrinology logo